BeOne Medicines AG

Common Name

BeOne Medicines

Country

Switzerland

Sector

Healthcare

Industry

Biotechnology

Employees

11,000

Ticker

688235

Exchange

SHANGHAI STOCK EXCHANGE

Website

www.beigene.com

Description

Beigene Ltd. is a global biotechnology company dedicated to developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The company is heavily... Show more

Financial Statements of BeOne Medicines

Below are the financial statements of BeOne Medicines, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in millions of USD	2024	2023
Current assets	—	—
Cash and cash equivalents	2,627.41^a	3,171.8^a
Accounts receivable, net	676.28^a	358.03^a
Inventories, net	494.99^a	416.12^a
Prepaid expenses and other current assets	192.92^a	257.47^a
Total current assets	3,991.59^a	4,203.41^a
Assets	—	—
Property, plant and equipment, net	1,578.42^a	1,324.15^a
Operating lease right-of-use assets	139.31^a	95.21^a
Intangible assets, net	51.1^a	57.14^a
Other non-current assets	160.49^a	125.36^a
Total non-current assets	1,929.32^a	1,601.86^a
Total assets	5,920.91^a	5,805.28^a
Current liabilities	—	—
Accounts payable	405^a	315.11^a
Accrued expenses and other payables	803.71^a	693.73^a
Tax payable	25.93^a	22.95^a
Operating lease liabilities, current portion	17.58^a	21.95^a
Research and development cost share liability, current portion	111.15^a	68^a
Short-term debt	851.53^a	688.37^a
Total current liabilities	2,214.9^a	1,810.11^a
Non-current liabilities	—	—
Long-term debt	166.48^a	197.62^a
Operating lease liabilities, non-current portion	44.28^a	22.25^a
Deferred tax liabilities	42.01^a	16.49^a
Research and development cost share liability, non-current portion	54.29^a	170.66^a
Other long-term liabilities	66.74^a	50.81^a
Total non-current liabilities	373.79^a	457.84^a
Total liabilities	2,588.69^a	2,267.95^a
Shareholders’ equity	—	—
Ordinary shares	0.14^a	0.14^a
Additional paid-in capital	12,087.91^a	11,598.69^a
Accumulated other comprehensive loss	-148.99^a	-99.45^a
Accumulated deficit	-8,606.84^a	-7,962.05^a
Total shareholders’ equity	3,332.22^a	3,537.33^a
Total liabilities and shareholders’ equity	5,920.91^a	5,805.28^a

Download Data

Verified Sources Behind BeOne Medicines’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore BeOne Medicines’s data sources below and access millions more through our Disclosure Search.

a. BeOne Medicines's Annual Report 2024

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

BeOne Medicines AG

Financial Statements of BeOne Medicines

Verified Sources Behind BeOne Medicines’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

CRISPR Therapeutics AG

Lonza Group AG

Siegfried Holding AG

Sonova Holding AG

Galenica AG

Straumann Holding AG